MacroGenics (MGNX) PT Raised to $21 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts MGNX Hot Sheet
Price: $2.25 -38.02%
Rating Summary:
13 Buy, 9 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
13 Buy, 9 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Stifel analyst Stephen Willey raised the price target on MacroGenics (NASDAQ: MGNX) to $21.00 (from $20.00) while maintaining a Buy rating.
You May Also Be Interested In
- MacroGenics reports Phase 1 data for MGC026 cancer drug at ESMO
- MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN
- Honeywell International (HON) PT Lowered to $261 at BMO Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
